Last reviewed · How we verify
Moxifloxacin ophthalmic solution 0.5%
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription. Used for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.
At a glance
| Generic name | Moxifloxacin ophthalmic solution 0.5% |
|---|---|
| Sponsor | Ophthalmic Consultants of Boston |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase; Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual mechanism allows it to be effective against a wide range of ocular pathogens. When applied topically as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.
Approved indications
- Bacterial conjunctivitis
- Bacterial keratitis
- Bacterial corneal ulcer
- Prophylaxis of bacterial infection following ocular surgery
Common side effects
- Conjunctival erythema
- Eye irritation
- Ocular discomfort
- Blurred vision
- Taste perversion
Key clinical trials
- Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis (NA)
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- PRO-232 in Patients Subjected to Cataract Surgery (PHASE3)
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects (PHASE1)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- The Effect of Gland Expression on the Regeneration of Meibomian Gland (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: